 |
| 14-May-13 | Reiterated |
Stifel |
Buy |
$44 → $54 |
|
| 18-Apr-13 | Reiterated |
Stifel |
Buy |
$37 → $44 |
|
| 12-Feb-13 | Initiated |
Robert W. Baird |
Outperform |
$27 |
|
| 12-Mar-12 | Initiated |
Brean Murray |
Buy |
$24 |
|
| 03-Jun-11 | Downgrade |
Robert W. Baird |
Outperform → Neutral |
$30 → $23 |
|
| 29-Mar-10 | Initiated |
Piper Jaffray |
Overweight |
$16 |
|
| 29-Jan-10 | Reiterated |
Credit Suisse |
Neutral |
$18 → $17 |
|
| 20-Feb-09 | Initiated |
ThinkEquity |
Buy |
$23 |
|
| 13-Feb-09 | Reiterated |
Credit Suisse |
Neutral |
$14 → $18 |
|
| 05-Feb-09 | Upgrade |
Robert W. Baird |
Neutral → Outperform |
$15 → $23 |
|
| 20-Nov-08 | Reiterated |
Stanford Research |
Buy |
|
|
| 29-Oct-08 | Downgrade |
Credit Suisse |
Outperform → Neutral |
$18 → $10 |
|
| 05-Sep-08 | Initiated |
Susquehanna Financial |
Positive |
|
|
| 04-Mar-08 | Reiterated |
Stanford Research |
Buy |
$34 → $26 |
|
| 04-Mar-08 | Reiterated |
Lehman Brothers |
Equal-weight |
$21 → $15 |
|
| 15-Jan-08 | Initiated |
Robert W. Baird |
Neutral |
$22 |
|
| 26-Oct-07 | Upgrade |
Stanford Research |
Hold → Buy |
$34 |
|
| 21-Aug-07 | Initiated |
Cowen & Co |
Outperform |
|
|
| 27-Apr-07 | Initiated |
Credit Suisse |
Outperform |
$39 |
|
| 09-Feb-07 | Reiterated |
Rodman & Renshaw |
Mkt Outperform |
$34 → $46 |
|
|
|
| 24-May-13 11:45AM | Royalty Pharma offer for Elan gets little support AP |
| 23-May-13 05:17PM | Royalty Pharma eases condition for Elan offer AP |
| 04:05PM | Theravance to Present at Investor Conferences in June 2013 Marketwired |
| 04:05PM | Theravance to Present at Investor Conferences in June 2013 Marketwire |
| 01:36PM | Elan rejects Royalty's $6.4 billion raised offer Reuters |
| 01:22PM | Elan rejects Royalty's $6.4 bln raised offer at Reuters |
| 08:06AM | Royalty Pharma eases condition for Elan offer AP |
| 08:01AM | Royalty cuts acceptance bar for Elan bid to 50 percent at Reuters |
| 08:00AM | Royalty cuts acceptance bar for Elan bid to 50 pct at Reuters |
| 21-May-13 06:30PM | When Savvy Dealmaking Borders on Reckless Spending at Motley Fool |
| 03:46PM | Elan Provides Strategic Update Zacks |
| 03:13PM | Analysts: Microsoft Has Big Potential and 3 More Research Notes to Browse at Wall St. Cheat Sheet |
| 01:30PM | Elan Continues To Make Baffling Strategic Decision at Investopedia |
| 10:02AM | THERAVANCE INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online |
| 07:07AM | Theravance pullback on Elan bid a buying opportunity, says Piper Jaffray at theflyonthewall.com |
| 20-May-13 06:06PM | Nasdaq stocks posting largest percentage decreases AP -6.52% |
| 04:05PM | Royalty Pharma Raises Elan Bid to $12.50 a Share in Cash at Bloomberg |
| 03:27PM | Royalty raises Elan bid, issues ultimatum to shareholders at Reuters |
| 02:33PM | Royalty Pharma increases bid for drugmaker Elan AP |
| 02:00PM | The 3 Deadliest Diseases in the U.S. at Motley Fool |
| 01:17PM | Nasdaq stocks posting largest percentage decreases AP |
| 12:01PM | Royalty Pharma Raises Elan Bid to $12.50 a Shae in Cash at Bloomberg |
| 10:02AM | THERAVANCE INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online |
| 03:35AM | Elan Makes Two Acquisitions for $380 Million at Bloomberg |
| 02:14AM | THERAVANCE INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online |
| 18-May-13 01:45PM | This Week in Biotech at Motley Fool |
| 17-May-13 11:27AM | The Billion Dollar COPD Deal: Who Gains The Most? at Seeking Alpha |
| 16-May-13 03:39PM | A Portfolio Construction Strategy with an Emphasis on High-Innovation, Breakthrough Biotech and Pharmaceutical Companies Wall Street Transcript |
| 09:30AM | THERAVANCE INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits EDGAR Online |
| 15-May-13 07:26PM | Theravance's CEO Presents at Bank of America Merrill Lynch Health Care Conference (Transcript) at Seeking Alpha |
| 01:42PM | Theravance Looks to Reward Shareholders by Splitting Into Two Distinct Companies at Motley Fool |
| 14-May-13 04:00PM | Elan in Royalty Deal with THRX Zacks |
| 02:11PM | Nasdaq stocks posting largest percentage increases AP |
| 02:04PM | Analysts: BlackBerrys MDM Is Underappreciated and 3 More Research Notes to Read at Wall St. Cheat Sheet |
| 09:06AM | Today's Market News To Trade On: 5 Stocks Moving On News at Seeking Alpha |
| 08:44AM | Who Benefits From This Market Moving Biotechnology Partnership? at Motley Fool |
| 08:16AM | Theravance price target raised to $48 from $38 at RW Baird theflyonthewall.com |
| 13-May-13 06:06PM | Do These Top Stock Picks Have More Room to Grow? at Motley Fool +17.92% |
| 06:03PM | Nasdaq stocks posting largest percentage increases AP |
| 05:40PM | Diversifying Royalties at a Hefty Cost at Motley Fool |
| 05:20PM | Glaxo/THRX's Breo Ellipta Gets FDA Nod Zacks |
| 05:14PM | Post Holdings, Tesla, Overstock.com are big movers AP |
| 05:13PM | Stocks Finish Flat as Earnings Wind Down at TheStreet |
| 04:37PM | Blue Chips Decline at The Wall Street Journal |
| 04:28PM | Why Did This Biotech Soar? at Motley Fool |
| 04:25PM | On The Fly: Closing Wrap at theflyonthewall.com |
| 04:17PM | Elan to Pay $1 Billion for Stake in Theravance Royalties at Bloomberg |
| 04:04PM | Billionaire Seth Klarman's Long-Term Stock Picks at Seeking Alpha |
| 04:00PM | Stocks End Flat Despite Strong Retail Sales Hot Stock Minute |
| 02:07PM | Stocks Retreat at The Wall Street Journal |
| 01:40PM | Why Theravance Shares Soared Again at Motley Fool |
| 01:34PM | Monday Sector Leaders: Biotechnology, Drugs at Forbes |
| 01:18PM | Nasdaq stocks posting largest percentage increases AP |
| 12:59PM | Elan enters $1B royalty deal with Theravance AP |
| 12:55PM | Apple Rumored to Receive InvenSense Parts and 2 Other Hot Stocks to Watch at Wall St. Cheat Sheet |
| 12:20PM | On The Fly: Midday Wrap at theflyonthewall.com |
| 12:14PM | Theravance and Elan Enter Into a 1 Billion Dollar Royalty Participation Agreement (Transcript) at Seeking Alpha |
| 11:38AM | Fed News Weighs on Stocks at The Wall Street Journal |
| 11:36AM | News Summary: Elan enters $1B deal with Theravance AP |
| 11:16AM | Theravance Stock Hits High On $1 Billion Elan Deal at Investor's Business Daily |
| 10:53AM | Fed News Weighs on Stocks at The Wall Street Journal |
| 09:56AM | Stocks Weaken Despite Retail Data at The Wall Street Journal |
| 09:52AM | Elan-Theravance deal a big boost for Baupost, Fidelity at Reuters |
| 09:41AM | [video] Faber Report: Elan Strikes Deal With Theravance at CNBC |
| 09:38AM | Did Elan Just Overpay On Theravance To Spurn Its Hostile Suitor? at Forbes |
| 09:25AM | On The Fly: Pre-market Movers at theflyonthewall.com |
| 09:17AM | Stocks to Watch: Theravance, Endo Health, Perion Network at The Wall Street Journal |
| 08:57AM | Stock Futures Pare Losses After Retail Sales Number at TheStreet |
| 08:30AM | Theravance surges on royalty deal optionMONSTER |
| 08:30AM | Theravance surges on Elan royalty deal optionMONSTER |
| 08:18AM | Elan's $1 billion drug royalty deal aids bid defense Reuters |
| 08:16AM | Elan's $1 billion drug royalty deal aids bid defense Reuters |
| 08:06AM | Elan enters $1B royalty deal with Theravance AP |
| 07:27AM | Morning Briefing: 10 Things You Should Know at TheStreet |
| 06:59AM | Dimon Talks of Quitting, Post Cereal Jumps Ahead of Earnings Hot Stock Minute |
| 05:37AM | Stocks to Watch: Elan, Theravance, Take-Two TheStreet |
| 02:42AM | InPlay: Theravance and Elan (ELN) enter into a $1.0 bln royalty participation agreement related to four respiratory programs with GlaxoSmithKline (GSK) Briefing.com |
| 02:14AM | Elan strikes $1 billion royalty deal with Theravance at Reuters |
| 02:12AM | Elan strikes $1 bln royalty deal with Theravance at Reuters |
| 02:03AM | BRIEF-Elan agrees $1 bln royalty deal with Theravance at Reuters |
| 02:00AM | Theravance and Elan Enter Into a $1.0 Billion Royalty Participation Agreement Marketwired |
| 02:00AM | Theravance and Elan Enter Into a $1.0 Billion Royalty Participation Agreement Marketwire |
| 02:00AM | Elan to Pay $1 Billion for Stake in Theravance Royalties at Bloomberg |
| 12-May-13 11:24PM | THERAVANCE INC Files SEC form 8-K, Regulation FD Disclosure EDGAR Online |
| 11-May-13 11:30AM | This Week in Biotech at Motley Fool |
| 10-May-13 04:20PM | Glaxo, Theravance Win Approval for Lung Disease Treatment at Bloomberg +11.59% |
| 04:02PM | Why Theravance Shareholders Can Breathe Easier at Motley Fool |
| 03:59PM | BREO ELLIPTA gains US approval for the treatment of COPD PR Newswire |
| 03:07PM | 4 Stocks Spiking on Big Volume at TheStreet |
| 01:22PM | Theravance, Glaxo Stocks Rise On Lung Drug Approval at Investor's Business Daily |
| 12:54PM | Glaxo, Theravance Win Approval for Lung Disease Treatment at Bloomberg |
| 12:38PM | InPlay: Theravance and GlaxoSmithKline (GSK) confirm BREO ELLIPTA gains U.S. approval for the treatment of COPD Briefing.com |
| 12:37PM | BREO(TM) ELLIPTA(TM) Gains US Approval for the Treatment of COPD Marketwired |
| 12:37PM | BREO(TM) ELLIPTA(TM) Gains US Approval for the Treatment of COPD Marketwire |
| 12:23PM | [$$] FDA Approves Glaxo Drug for Lung Disease at The Wall Street Journal |
| 11:35AM | U.S. FDA approves Glaxo/Theravance drug for COPD lung disease at Reuters |
| 11:15AM | FDA approves Breo Ellipta to treat chronic obstructive pulmonary disease theflyonthewall.com |
| 06:07AM | THERAVANCE INC Files SEC form 8-K, Other Events EDGAR Online |
| 09-May-13 11:03PM | THERAVANCE INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits EDGAR Online |
| 08-May-13 01:22PM | Double-Digit Returns from the Biotechnology Strategy at Motley Fool |
|
|
| Theravance, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule medicines primarily for therapeutic areas of respiratory diseases, bacterial infections, and central nervous system (CNS)/pain. The company's respiratory programs with GlaxoSmithKline plc include RELVAR or BREO, an inhaled corticosteroid/long-acting beta2 agonist combination treatment, comprising fluticasone furoate and vilanterol (VI), for the treatment of chronic obstructive pulmonary disease (COPD) and asthma; ANORO, a once-daily investigational medicine, combining a long-acting muscarinic antagonist (LAMA), umeclidinium, and a LABA, VI, for the treatment of COPD; and GSK961081, an investigational, single molecule bifunctional bronchodilator with both muscarinic antagonist and beta2 receptor agonist activities. Its bacterial infections program includes VIBATIV for the treatment of nosocomial pneumonia; and its CNS/pain programs consist of TD-1211, a multivalent inhibitor of the mu opioid receptor for alleviating gastrointestinal side effects of opioid therapy without affecting analgesia, and TD-9855, which is in Phase II study in adults with attention-deficit/hyperactivity disorder and fibromyalgia. The company's theravance respiratory program includes TD-4208, an investigational inhaled LAMA in Phase IIb study to evaluate the safety and pharmacokinetics of multiple doses; and gastrointestinal motility dysfunction program consists of Velusetrag, an oral, investigational medicine dosed once-daily in Phase II proof-of-concept study to evaluate velusetrag for the treatment of patients with diabetic or idiopathic gastroparesis through collaboration with Alfa Wassermann. It also has collaborations with Merck & Co. and R-Pharm CJSC. The company was formerly known as Advanced Medicine, Inc. and changed its name to Theravance, Inc. in April 2002. Theravance, Inc. was founded in 1996 and is headquartered in South San Francisco, California. |
|
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| Brinkley David L | Head of Business Dev. | May 13 | Option Exercise | 34.00 | 16,129 | 548,386 | 71,129 | May 15 07:07 PM | | Brinkley David L | Head of Business Dev. | May 13 | Sale | 40.33 | 16,129 | 650,483 | 55,000 | May 15 07:07 PM | | Brinkley David L | Head of Business Dev. | May 03 | Option Exercise | 29.65 | 16,129 | 478,225 | 71,129 | May 07 07:01 PM | | Brinkley David L | Head of Business Dev. | May 03 | Sale | 34.77 | 16,129 | 560,805 | 55,000 | May 07 07:01 PM | | Winningham Rick E | Chief Executive Officer | Apr 30 | Option Exercise | 9.69 | 385,161 | 3,731,247 | 977,083 | May 02 07:00 PM | | Aguiar Michael W | Sr VP, Chief Financial Officer | Apr 30 | Option Exercise | 17.91 | 170,879 | 3,060,443 | 313,365 | May 02 07:04 PM | | Brinkley David L | Head of Business Dev. | Apr 30 | Option Exercise | 6.15 | 8,333 | 51,248 | 72,104 | May 02 07:05 PM | | Mammen Mathai | SVP, Research & Early Clin Dev | Apr 30 | Sale | 33.74 | 7,000 | 236,164 | 205,976 | May 02 07:06 PM | | Brinkley David L | Head of Business Dev. | Apr 30 | Sale | 33.76 | 17,104 | 577,490 | 55,000 | May 02 07:05 PM | | Aguiar Michael W | Sr VP, Chief Financial Officer | Apr 30 | Sale | 33.80 | 170,879 | 5,776,341 | 142,486 | May 02 07:04 PM | | Winningham Rick E | Chief Executive Officer | Apr 30 | Sale | 33.64 | 255,532 | 8,597,169 | 721,551 | May 02 07:00 PM | | Mammen Mathai | SVP, Research & Early Clin Dev | Feb 20 | Sale | 22.14 | 7,000 | 154,980 | 212,976 | Feb 22 07:03 PM | | Mammen Mathai | SVP, Research & Early Clin Dev | Jan 11 | Option Exercise | 3.10 | 14,510 | 44,981 | 220,438 | Jan 14 07:04 PM | | Mammen Mathai | SVP, Research & Early Clin Dev | Nov 14 | Option Exercise | 3.10 | 5,161 | 15,999 | 210,802 | Nov 16 07:01 PM | | Mammen Mathai | SVP, Research & Early Clin Dev | Nov 02 | Sale | 21.45 | 7,000 | 150,162 | 205,641 | Nov 06 07:01 PM | | Aguiar Michael W | Sr VP, Chief Financial Officer | Aug 27 | Sale | 27.33 | 20,561 | 561,855 | 132,486 | Aug 28 07:01 PM | | Aguiar Michael W | Sr VP, Chief Financial Officer | Aug 24 | Option Exercise | 17.91 | 4,121 | 73,807 | 157,168 | Aug 28 07:01 PM | | Brinkley David L | Head of Business Dev. | Aug 24 | Sale | 27.50 | 3,483 | 95,783 | 60,241 | Aug 28 07:02 PM | | Aguiar Michael W | Sr VP, Chief Financial Officer | Aug 24 | Sale | 28.01 | 4,121 | 115,429 | 153,047 | Aug 28 07:01 PM | | Mammen Mathai | SVP, Research & Early Clin Dev | Aug 13 | Sale | 25.74 | 25,000 | 643,461 | 212,285 | Aug 15 07:05 PM | | Aguiar Michael W | Sr VP, Chief Financial Officer | Aug 07 | Option Exercise | 16.25 | 60,000 | 975,000 | 217,924 | Aug 09 07:00 PM | | Aguiar Michael W | Sr VP, Chief Financial Officer | Aug 07 | Sale | 27.04 | 60,000 | 1,622,400 | 157,924 | Aug 09 07:00 PM | | Winningham Rick E | Chief Executive Officer | Aug 03 | Option Exercise | 3.10 | 145,161 | 449,999 | 667,007 | Aug 07 07:02 PM | | Brinkley David L | Head of Business Dev. | Aug 03 | Option Exercise | 7.88 | 106,757 | 840,955 | 190,698 | Aug 07 07:03 PM | | Brinkley David L | Head of Business Dev. | Aug 03 | Sale | 27.92 | 123,917 | 3,459,763 | 66,781 | Aug 07 07:03 PM | | Winningham Rick E | Chief Executive Officer | Aug 03 | Sale | 27.95 | 75,749 | 2,117,306 | 591,258 | Aug 07 07:02 PM | | Aguiar Michael W | Sr VP, Chief Financial Officer | May 29 | Sale | 22.29 | 20,000 | 445,800 | 157,924 | May 31 07:27 PM |
|
|
|
|
|
|
